Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.60 |
| ▸ | RXRA | P19793 | 2/20 | 0.57 |
| ▸ | RXRB | P28702 | 2/20 | 0.57 |
| ▸ | RXRG | P48443 | 2/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.54 |
| ▸ | MAOB | P27338 | 6/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
| ▸ | PYGM | P11217 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10784618 | 0.83 | RXRA (0.68) | NR4A2RXRARXRBRXRGSRD5A2 | |
| SCHEMBL16136222 | 0.83 | PTPN11 (0.55) | PYGLPYGM | |
| SCHEMBL7161222 | 0.81 | MAOB (0.65) | NR4A2SRD5A2MAOBCYP1A2CYP2C9 | |
| SCHEMBL5112581 | 0.79 | MAOB (0.57) | NR4A2RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL2902027 | 0.78 | RXRA (0.68) | NR4A2RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL1115026 | 0.77 | MEN1 (0.67) | NR4A2SRD5A2MRGPRX4MAOBNPC1 | |
| SCHEMBL2326578 | 0.77 | MEN1 (0.61) | NR4A2SRD5A2MRGPRX4MAOBNPC1 | |
| SCHEMBL2910095 | 0.77 | MAOB (0.69) | NR4A2RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL30704729 | 0.77 | NR4A1 (0.66) | NPC1RAB9A | |
| SCHEMBL9197822 | 0.77 | NR4A1 (0.66) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-08-06 | — | — | US | disclosed |
| CN-105307655-B | Pyridazinone compound and its be used to prepare treatment tumour shape fibrosis drug application | 弗拉特利发现实验室有限责任公司 | 2019-05-03 | — | — | CN | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-9783529-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783529-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| CN-105307655-A | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB | 2016-02-03 | — | — | CN | disclosed |
| EP-2968323-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | Flatley Discovery Lab (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150005300-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2014160440-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005300-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PNPO | NR4A2 2547/4885RXRA 822/4885RXRB 411/4885 |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PNPO | NR4A2 2547/4885RXRA 822/4885RXRB 411/4885 |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | CFTR, SLC26A4, PNPO | NR4A2 2547/4885RXRA 822/4885RXRB 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.